Reports Q1 revenue 1.11B yen vs. 1.21B yen last year. Takeda (TAK) chief financial officer, Milano Furuta, commented: “The impact of VYVANSE generic erosion on Takeda’s FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May. Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Alkermes selling off on limited data disclosure, says BofA
- Takeda receives FDA clearance for HyHub, HyHub Duo
- Avidity, Phathom mentioned as potential takeout targets at Needham
- Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
- Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton